Výsledky vyhledávání - "Shannon Schneider"

Efficacy and Safety of Tralokinumab in US Adults with Moderate-to-Severe Atopic Dermatitis: A Post-hoc Analysis of ECZTRA3

Autor: Boni Elewski, Matthew Zirwas, Azra Kurbasic, Shannon Schneider, Ami Claxton, Jonathan Silverberg

Publikováno v: SKIN The Journal of Cutaneous Medicine. 7:686-695

Background: Tralokinumab, a monoclonal antibody that specifically neutralizes interleukin (IL)-13, is approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). Tralokinumab was studied in ECZTRA3 (NCT03363854), a randomized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e16bef10a981e04b50d51f266ed3adfe
https://doi.org/10.25251/skin.7.2.5

Zobrazit plný text záznamu

308 Tralokinumab provides other clinically meaningful improvements in adolescents with moderate-to-severe atopic dermatitis who did not achieve IGA 0/1 at week 16

Autor: Amy Paller, Andrew Blauvelt, Weily Soong, Chih-ho Hong, Marie L A Schuttelaar, Shannon Schneider, Marie Holst Moerch, Eric Simpson

Publikováno v: British Journal of Dermatology. 188

In the monotherapy phase 3 trial (ECZTRA 6, NCT03526861) in adolescents with moderate-to-severe atopic dermatitis (AD) treated with tralokinumab, IGA of clear/almost clear skin (IGA 0/1) at week 16 was a primary endpoint. IGA 0/1 can be a high standa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f8880a04da87dd8a460d9fb1a7b36068
https://doi.org/10.1093/bjd/ljac140.008

Zobrazit plný text záznamu

Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Autor: Tiffany Mayo, April Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdaile, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew Alexis

Publikováno v: SKIN The Journal of Cutaneous Medicine. 6:s74

N/A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a996ff84f8ed1eb2192c2deda0feb8
https://doi.org/10.25251/skin.6.supp.74

Zobrazit plný text záznamu

Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials

Autor: Tiffany Mayo, April Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdaile, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew Alexis

Publikováno v: SKIN The Journal of Cutaneous Medicine. 6:s76

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d64fb9005e8cd00484115e90a4480a6d
https://doi.org/10.25251/skin.6.supp.76

Zobrazit plný text záznamu

Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)

Autor: Eric L, Simpson, Andreas, Wollenberg, Weily, Soong, Louise Abildgaard, Steffensen, Azra, Kurbasic, Shannon, Schneider, John, Zoidis, Jonathan I, Silverberg

Publikováno v: Annals of Allergy, Asthma & Immunology. 129:592-604.e5

Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe atopic dermatitis and additional efficacy in a long-term extension t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0bf4ee9bee17255886c072d33c1f39c
https://doi.org/10.1016/j.anai.2022.07.007

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání